Haixiang Pharmaceutical (002099.SZ): Achieved revenue of 2.172 billion yuan in 2023, a year-on-year decrease of 19.68%

On April 28, Ge Longhui | Haixiang Pharmaceutical (002099.SZ) released its 2023 annual report. Operating income for the reporting period was 2.112 billion yuan, down 19.68% year on year; net profit attributable to shareholders of listed companies - 420 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 341 million yuan; basic earnings per share - 0.26 yuan.

Gelonghui FinanceApr 28 21:34

Haixiang Pharmaceutical (002099.SZ) announced its 2023 annual results, with a net loss of 420 million yuan, changing from profit to loss

Haixiang Pharmaceutical (002099.SZ) released its 2023 annual report. The company's revenue was 2.172 billion yuan,...

Zhitong FinanceApr 28 17:30

Haixiang Pharmaceutical (002099.SZ) announced first-quarter results, net profit of 32.5933 million yuan, a year-on-year decrease of 22.58%

Haixiang Pharmaceutical (002099.SZ) released its report for the first quarter of 2024. The company's revenue was 528 million yuan...

Zhitong FinanceApr 28 17:27

Hisoar Pharma's Unit Passes German Health Regulator's Inspection

Zhejiang Hisoar Pharmaceutical's (SHE:002099) unit, Zhejiang Haixiang Sichuan Pharmaceutical, obtained good manufacturing practice certificates from Germany's health regulator for the production of it

MT NewswiresApr 18 14:27

Haixiang Pharmaceutical (002099.SZ): Subsidiary passed EU GMP certification

Gelonghui April 17 丨 Haixiang Pharmaceutical (002099.SZ) announced that its wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical Co., Ltd. has received GMP certificates for clindamycin hydrochloride APIs and clindamycin phosphate APIs issued by the Hamburg Ministry of Health and Consumer Protection (BJV), Germany. Chuannan Pharmaceutical is the company's main API production base. It once again passed the EU GMP certification in 2024, indicating that the quality system of Chuannan Pharmaceutical has always been in line with international standards, and that Chuannan Pharmaceutical's related products meet the EU market entry requirements. Chuannan Pharmaceutical's EU GMP certification this time will help the company explore and expand high-end markets in Europe and the US

Gelonghui FinanceApr 17 15:42

Express News | Haixiang Pharmaceutical: A wholly-owned subsidiary obtained EU GMP certificates for clindamycin hydrochloride APIs and clindamycin phosphate APIs

BreakingsApr 17 15:41